[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.30 1.06% 28.50 28.00 29.00 29.00 28.50 29.00 8,166 15:26:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -9.6 -8.1 - 65

C4x Discovery Share Discussion Threads

Showing 2526 to 2549 of 2625 messages
Chat Pages: 105  104  103  102  101  100  99  98  97  96  95  94  Older
DateSubjectAuthorDiscuss
01/5/2021
07:39
Bingham & Dixi nailed it !!!
bloomberg2
01/5/2021
07:38
Dixhttps://www.thetimes.co.uk/article/clive-dix-its-beyond-belief-that-we-got-the-covid-vaccines-ready-in-less-than-a-year-0hgdrb3gz?shareToken=20d5b693830b04de09e16c2b955b27b3
ayl30
29/4/2021
17:52
I also think it is strange there was no movement on today TU
charlie9038
29/4/2021
14:04
I find it strange that there is little movement in share price on release of interims.
astorcourt
29/4/2021
11:26
I think that takes in the INDV deal and the new one. The next INDV payment cant be too far away.
alloa2003
29/4/2021
10:23
The statement "a roadmap of potential cash milestones over the next 12-24 months" is ambiguous. Does it mean anytime from month 1 onwards or from month 13 to 24? In this regard I am expecting a milestone payment from Indivior on the publication of their P1 single dose results and possibly a second associated with the multiple ascending dose trial. Any thoughts?
t0pgrader
29/4/2021
09:08
MC 94m at 41p seems a bargain with the TU today. Anyone good on here with figures?
charlie9038
29/4/2021
08:22
Good progress across the portfolio and so reassuring to see such a solid cash position.
bamboozler
29/4/2021
07:41
Looks good to me: a €414 million agreement § Exclusive worldwide licensing agreement with Sanofi for C4XD's IL-17A oral inhibitor programme worth up to €414 million including: § €7 million upfront § €407 million in potential development, regulatory and commercialisation milestones, of which €11 million is in pre-clinical milestones § Potential for single-digit royalties
charlie9038
28/4/2021
16:44
I wonder what the figures will hold tomorrow morning?
alloa2003
21/4/2021
18:11
That's very interesting Bamboozler, thanks for posting.
alanrussell
21/4/2021
17:24
https://www.proactiveinvestors.co.uk/companies/news/947260/c4x-discovery-happy-in-the-pre-clinical-world-as-partner-list-grows-947260.html
bamboozler
20/4/2021
17:57
Yip, agree. The Americans love a company with huge hope value - just look at Tesla!
alloa2003
20/4/2021
15:14
New board appointment which to be fair is just what the doctor ordered:- "20 April 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces the appointment of Simon Harford as Non-Executive Director with immediate effect. Simon joins C4XD with more than 30 years of significant financial and investor relations expertise in global pharmaceutical companies. Simon is currently CFO at Albireo Pharma Inc., a NASDAQ-listed biotech company where he has raised more than $200 million in equity financing and was previously CFO of Parexel International Inc., a global clinical research organisation, which was acquired by private equity in 2017. Prior to this, Simon held various financial leadership roles at GSK, including SVP Finance, Global Pharmaceuticals. During his tenure, he was responsible for finance in all pharmaceutical markets globally and was a member of the Global Pharmaceutical Operations Committee. Simon also held key financial management roles at Eli Lilly and Company over two decades including Vice President and Controller, CFO and Executive Director Finance for Europe, Middle East and Africa (EMEA) and led the global investor relations function as Executive Director of Investor Relations. He also received the Lilly, Chairman's Ovation Award 2004 for outstanding achievement to Lilly. Eva-Lotta Allan, Chairman of C4X Discovery, said: "Simon brings a wealth of global pharmaceutical expertise across key financial markets, including the US where he is based. His deep understanding of global pharmaceutical financial strategy will be invaluable as we continue to grow C4XD and expedite major out-licensing deals such as our recent deals with Sanofi and Indivior. We welcome Simon to the Board and look forward to working closely with him." Simon Harford, incoming Non-Executive Director, added: "I am delighted to be joining the C4XD Board at this stage of the Company's development. C4XD has made great progress in the execution of its strategy, which the recent deal with Sanofi further validates. The Company's technologies are able to deliver high quality and differentiated drug candidates for development by pharma and biotech companies and I look forward to working with the Board to continue growing the Company and delivering shareholder value."
alloa2003
20/4/2021
14:41
Nibbled a few following the stream of buys (highly speculative, high risk - exit if no traction) but no idea where these streams originate nowadays. Is it: Twitter? Facebook share groups? Telegram groups? Reddit or some other UK equivalent group? Other private chat sites? Tip from a publication? Tip from some other known or unknown prominent person? You even have TIK TOK nowadays with folk following social influencers into investments nowadays. By the time you work it out, the price has shifted so often worth just having a little nibble to see if there is any momentum and then just come out if it doesn't crack on. Anywho, I'm sure someone might be able to shed some light. All imo DYOR
sphere25
20/4/2021
14:38
There was no milestone payment received from Indivior at the outset of the P1 clinical trial so there could be one upon its conclusion. FWIW C4XD interim results were 29 / 4 last year.
t0pgrader
20/4/2021
14:36
Oh...I will do!!!
bamboozler
20/4/2021
14:32
@bamboozier - might perhaps relate to the impeding completion of the Indivior P1 trial for INDV2000?
t0pgrader
20/4/2021
14:30
Don't worry Hold on & enjoy the ride ;)
charlie9038
20/4/2021
14:17
Anyone got any idea what caused today's sudden turnaround?It looks quite odd.
bamboozler
18/4/2021
07:58
Yes, I've seen that about the delivery system too. But my understanding is that it's in addition to the idea that their discovery process is also intended to increase success rates. So on the two licensed deals there are double factors increasing the standard probabilities of making it through trials. They're obviously still a long shot but at least this week there are now two long shots rather than one! I'm right on board with the view that the main takeaway from the Sanofi deal isn't really the potential revenue but that it's further proof of concept and that the revenue boost short term allows other projects to progress with less chance of another capital raise needed.
1aconic
16/4/2021
21:52
That is my understanding as well - they are working on quasi existing treatments but a different type of delivery system. That was my understanding from one of Clive's early videos. Nothing is guaranteed with the treatments but I dont think the risk is as high as "traditional" new drugs. I stand corrected if I am wrong.
alloa2003
16/4/2021
08:38
Good video - thanks for sharing. I think it's less than 10% too but my understanding is that they believe the odds to be higher due to the way the molcules are discovered. As I understand it, the whole thesis for C4X's existance is to get molecules more likely to work and improve success rates in later stages.
1aconic
14/4/2021
14:44
I think it is fewer than 10% Dave
toffeeman
Chat Pages: 105  104  103  102  101  100  99  98  97  96  95  94  Older
ADVFN Advertorial
Your Recent History
LSE
C4XD
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211019 00:34:59